Amgen

Why trials sponsored by Amgen stopped, in this sample of ClinicalTrials.gov.

18 stopped trials with a clear reason; 50% ended for non-scientific reasons.

Where it ranks

• #5 of 90 sponsors by share of trials stopped for: regulatory or ethics problems (11%).
• #5 of 90 sponsors by share of trials stopped for: futility (17%).
• #2 of 90 sponsors by share of trials stopped for: safety (22%).

Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.

Trials

• Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
  NCT06910709 · TERMINATED · funding business
  “Business Decision”
• A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
  NCT05267470 · TERMINATED · funding business
  “Business decision not due to safety concerns”
• A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
  NCT04933695 · TERMINATED · futility
  “Futility”
• Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
  NCT03912337 · TERMINATED · other
  “Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]”
• Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
  NCT03433755 · TERMINATED · funding business
  “Prematurely Discontinued Amgen decision”
• An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
  NCT03619187 · WITHDRAWN · funding business
  “Sponsor decision”
• A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
  NCT03392064 · SUSPENDED · other
  “Study on enrollment hold, may potentially resume. No active subjects on trial.”
• Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
  NCT03638128 · TERMINATED · safety
  “The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants”
• Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
  NCT03276728 · TERMINATED · funding business
  “Terminated (Decision by the Sponsor. The study was not terminated due to a safety reason.)”
• A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
  NCT02291614 · TERMINATED · funding business
  “The study was terminated because of immunogenicity and business decision.”
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
  NCT01881789 · TERMINATED · safety
  “A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.”
• Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
  NCT01902290 · TERMINATED · futility
  “Study terminated early due to lack of efficacy observed following interim analysis in Q2 2015. Study Closed once all sites were closed in eClinical”
• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
  NCT01439867 · TERMINATED · regulatory
  “Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.”
• Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
  NCT01416428 · TERMINATED · safety
  “A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.”
• Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
  NCT01199302 · TERMINATED · safety
  “The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups.”
• Safety and Efficacy of AMG 827 in Subjects With RA
  NCT01059448 · TERMINATED · futility
  “Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)”
• Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
  NCT00156962 · TERMINATED · regulatory
  “Regulatory decision not to proceed”
• Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis
  NCT00078806 · TERMINATED · slow accrual
  “the study was terminated because of slow enrollment”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.